QBD-OPTIMISED AND VALIDATED RP-HPLC METHOD DEVELOPMENT USING BOX-BEHNKEN DESIGN FOR QUANTITATIVE EVALUATION OF DASATINIB IN LIPID NANOPARTICLES
DOI:
https://doi.org/10.22159/ijap.2026v18i3.58317Keywords:
Dasatinib, Lipid nanoparticles, Reversed-phase high performance liquid chromatography, Quality by design, Accuracy, ValidationAbstract
Objective: A robust and reliable analytical method for the quantification of dasatinib (DSB) is required for the design of such lipid nanoparticle (LNP) systems, as excipients may interfere and the drug may be unstable during analysis.
Methods: A Quality by Design (QbD) approach was employed in the development and optimization of a reversed-phase high performance liquid chromatography (RP-HPLC) method using a box-behnken design (BBD) to explore the relationships between the important variables in the chromatographic process. The optimized method was validated as per ICH guidelines, and it was found to be linear in the range of 50 to 5000 ng/mL with a good concentration-response relationship.
Results: The method demonstrated excellent sensitivity, with limits of detection and limits of quantitation of 3.16 ng/mL and 9.56 ng/mL, respectively. Precision testing showed the method had good repeatability and percentage relative standard deviation (%RSD) within acceptable ranges. The method also demonstrated specificity via photodiode array detector (PDA) peak purity analysis, which yielded a purity index of 0.999, indicating no interference from excipients or degradation products. Forced degradation testing Experiments provided evidence that DSB was exhibited 13.91% degradation under acidic conditions (0.1 N HCl, room temperature (RT)) and 13.42% degradation under alkaline conditions (0.1 N NaOH, RT) and that the separation of intact Drug from Degradation Products supported the method's ability as a stability-indicating method on the dasatinib lipid nanoparticles (DSB-LNPs), with a 97.43% of percentage encapsulation efficiency (%EE) , 3.98% of percentage drug loading (%DL), supporting its use in routine analysis.
Conclusion: The validated QbD approach-based RP-HPLC method is robust, sensitive, and stability-indicating; therefore, it is the best choice for routine analysis of DSB in Bulk and LNPs.
References
1. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021 Dec 1;96(12):1679–705. doi:10.1002/ajh.26367 PubMed PMID: 34625994.
2. Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia. 2020 Feb 1;34(2):488–98. doi:10.1038/s41375-019-0563-0 PubMed PMID: 31477798.
3. Keerikkadu M, Bangera PD, Tippavajhala VK, Rathnanand M. Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success. AAPS PharmSciTech. 2025 May 13;26(5):131. doi:10.1208/s12249-025-03130-7
4. Singh A, Jaiswal V, Bisht S. ADVANCES IN COCRYSTALS OF ANTICANCER AGENTS: FORMULATION STRATEGIES AND THERAPEUTIC IMPLICATIONS. Int J Pharm Pharm Sci. 2024 Jun 1;27–32. doi:10.22159/ijpps.2024v16i6.51044
5. Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Leukemia. 2024 Apr;38(4):781–7. doi:10.1038/s41375-024-02145-6
6. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O’Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 Apr 1;126(7):1502–11. doi:10.1002/cncr.32627 PubMed PMID: 31999839.
7. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97(11):1413–8. doi:10.1002/ajh.26689
8. Bangera PD, Shukla E, Kara DD, Roychowdhury R, Keerikkadu M, Tippavajhala VK, Rathnanand M. DEVELOPMENT AND ASSESSMENT OF A SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR ENHANCED SOLUBILITY OF DASATINIB. Int J Appl Pharm. 2025 Jan 7;123–32. doi:10.22159/ijap.2025v17i1.52404
9. Dharuman N, Lakshmi KS, Krishnan M. Environmental benign RP-HPLC method for the simultaneous estimation of anti-hypertensive drugs using analytical quality by design. Green Chem Lett Rev. 2023 Jan 2;16(1):2214176. doi:10.1080/17518253.2023.2214176
10. Perumal DD, Krishnan M, Lakshmi KS. Eco-friendly based stability-indicating RP-HPLC technique for the determination of escitalopram and etizolam by employing QbD approach. Green Chem Lett Rev. 2022 Jul 3;15(3):671–82. doi:10.1080/17518253.2022.2127334
11. Devdikar S, Shetkar B, Satpute K, Lohiya G, Sonvane S, Kore S, Kulkarni Y, Syed SM. Implementation of QbD approach in RP-HPLC method optimization and validation for concurrent estimation of Deflazacort and Tamsulosin hydrochloride under ICH Q14 and Q2R2 framework. Curr Pharm Anal. 2025 Nov 1;21(10):486–99. doi:10.1016/j.cpan.2025.09.003
12. Kannaiah KP, Chanduluru HK, Lotfy HM, Obaydo RH, El Hamd MA, Alshehri S, A. Mahdi W, Nessim CK. Integrative AQbD, up-to-date greenness, and whiteness tools for evaluation of a sustainable RP-HPLC method used for simultaneous separation of triple antihypertensive combination therapy as a model. Sustain Chem Pharm. 2023 Dec 1;36:101288. doi:10.1016/j.scp.2023.101288
13. El-Sayed HM, Abdellatef HE, Hendawy HAM, El-Abassy OM, Ibrahim H. DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach. Microchem J. 2023 Jul 1;190:108730. doi:10.1016/j.microc.2023.108730
14. Alluri NR, Bandlamudi MR, Kuppusamy S, Morais SR. Implementation of the QbD Approach to the Analytical Method Development and Validation for the Estimation of the Treprostinil Injection Dosage Form by RP-HPLC. ACS Omega. 2025 May 6;10(17):17827–35. doi:10.1021/acsomega.5c00373
15. Akabari AH, Patel SK, Shah KV, Patel A, Modi D, Sen AK, Ramani VD, Shah DP, Patel SP. Analytical quality by design (AQbD) methodology for concurrent determination of perindopril erbumine and moxonidine hydrochloride using RP-HPLC with an eco-friendly evaluation. Discov Chem. 2025 Jan 3;2(1):1. doi:10.1007/s44371-024-00067-x
16. Sonawane SN, Kurangi BK, Shelar OA, Jalalpure AA, Gawas N, Koli R. Quality by design assisted a stability indicating RP-HPLC method for the estimation of hesperidin in transfersome and marketed product. J Indian Chem Soc. 2025 Jan 1;102(1):101521. doi:10.1016/j.jics.2024.101521
17. Singh R, Dhalani J. A simple and expeditious RP-HPLC method for the simultaneous determination of commercially available seven pesticides formulations. Microchem J. 2025 Jan 1;208:112292. doi:10.1016/j.microc.2024.112292
18. Nassar MW, Serag A, Hasan MA, Kamel M. Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations. Sci Rep. 2025 Jul 15;15(1):25470. doi:10.1038/s41598-025-09904-0
19. Kumar A, Dhiman C, Kumar M, Kannappan N, Kumar D, Chourasia MK, Narayan KP. Development of a quality by design based hybrid RP-HPLC method for Glimepiride: Bioanalytical and industrial applications. J Appl Pharm Sci. 2025 Mar 5;15,(4):102–15. doi:10.7324/JAPS.2025.214654
20. Rmandić M, Rašević M, Stanković J, Zečević M, Otašević B, Protić A, Malenović A. Development and robust optimization of the RP-HPLC method for the determination of riociguat and its four impurities in tablets using the AQbD approach. J Pharm Biomed Anal. 2025 Jun 15;258:116742. doi:10.1016/j.jpba.2025.116742
21. Shelke RU, Ghatkar RP, Mogal RT, Rishipathak DD. Analytical quality by design approach to RP- HPLC method development, optimization and validation for simultaneous estimation of Dolutegravir and Rilpivirine. Anal Chem Lett. 2025 Sep 3;15(5):864–79. doi:10.1080/22297928.2025.2557474
22. Muanrit P, Poomirat S, Sakpakdeejaroen I. Validation of HPLC method for quantitative determination of zerumbone in the rhizome of Zingiber ottensii Valeton. Talanta Open. 2025 Aug 1;11:100405. doi:10.1016/j.talo.2025.100405
23. Kumar Prajapati S, Jain A, Bajpai M. Development and validation of the RP-HPLC method for quantification of tavaborole. Anal Methods. 2024;16(30):5280–7. doi:10.1039/D4AY00943F
24. Lambarki LZ, Jhilal F, Slimani L, El Hajji R, Bakkali F, Iskandar S, El Jemli M, Ihssane B, El Ghali W, Saffaj T. Comparison of approaches for assessing detection and quantitation limits in bioanalytical methods using HPLC for sotalol in plasma. Sci Rep. 2025 Feb 14;15(1):5472. doi:10.1038/s41598-024-83474-5
25. Sudhakar Gomte S, Chaturvedi S, Sharma N, Jain A. Development and validation of RP-HPLC method for simultaneous estimation of 5-fluorouracil and silibinin in corn-derived protein-polysaccharide nanocomplex: Forced degradation and mathematical modeling of drug release. Microchem J. 2024 Jun 1;201:110681. doi:10.1016/j.microc.2024.110681
26. Paul K, Gowda BHJ, Chandan RS. Development and validation of a novel RP-HPLC method for determination of Remdesivir: Investigation of the greenness for the proposed method. Results Chem. 2025 Jul 1;16:102382. doi:10.1016/j.rechem.2025.102382
27. Jaiswal R, Wadetwar R. DEVELOPMENT AND VALIDATION OF THE RP-HPLC METHOD FOR ESTIMATION OF CILNIDIPINE IN RAT PLASMA. Int J Pharm Pharm Sci. 2022 Oct 1;32–7. doi:10.22159/ijpps.2022v14i10.45940
28. Kir F, Dogan A, Sahin S. Development of a RP-HPLC method for simultaneous determination of atenolol, metoprolol tartrate and phenol red for in-situ rat intestinal perfusion studies. J Chromatogr B. 2024 Jul 1;1241:124160. doi:10.1016/j.jchromb.2024.124160
29. Sinha S, Rao Ravi P, Rajesh Rashmi S, Koumudi Devaraju L. Improving oral bioavailability of acalabrutinib using polymer–lipid hybrid nanoparticles: design, optimization, and in vivo pharmacokinetic evaluation. Nanoscale Adv. 2025;7(21):6874–87. doi:10.1039/D5NA00386E
30. Keerikkadu M, Bangera PD, Tippavajhala VK, Rathnanand M. An Overview on Lipid Nanocapsules: Exploring the Role in Precision Cancer Treatment and Lymphatic Drug Distribution. Adv Pharm Bull. 2025 Jun 1;15(2):248–67. doi:10.34172/apb.025.45109
31. Behdarvand N, Bikhof Torbati M, Shaabanzadeh M. Tamoxifen-loaded PLA/DPPE-PEG lipid-polymeric nanocapsules for inhibiting the growth of estrogen-positive human breast cancer cells through cell cycle arrest. J Nanoparticle Res. 2020 Aug 28;22(9):262. doi:10.1007/s11051-020-04990-9
32. Hirose R, Iharada T, Tsukagoshi K. Development and Evaluation of a Phase-Separation Mode in HPLC Through the Analysis of Multicomponent Analytes. Chromatographia. 2025 Dec 1;88(11):939–51. doi:10.1007/s10337-025-04449-w
33. Hu Z, Li Y, Zhou W, Gu X, Li B. Residue analysis, dissipation dynamics, and risk assessment of ipconazole in paddy environment by a modified QuEChERS/HPLC-MS method. J Food Compos Anal. 2025 Jun 1;142:107516. doi:10.1016/j.jfca.2025.107516
34. Zambre D, Hussain U, Sheikh S, Jaiswal S, Belgamwar V. Stability-indicating HPLC analysis of Azilsartan Medoxomil potassium: A QbD-based method development and validation. J Chromatogr B. 2025 Jun 1;1259:124599. doi:10.1016/j.jchromb.2025.124599
35. Aggarapu S, Galla R, Shaik NJ, Dasari SJ. Application of Plackett–Burman and Box–Behnken designs to develop a sensitive and robust HPLC method for quantifying hypolipidemic drugs, rosuvastatin and bempedoic acid in tablets. Future J Pharm Sci. 2025 May 26;11(1):61. doi:10.1186/s43094-025-00814-6
36. O’Neill R, Yoo O, Burcham P, Nguyen M, Lim LY. Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification. Molecules. 2025 Jul 5;30(13). doi:10.3390/molecules30132866
37. Thomas A, Varkey J. DEVELOPMENT AND VALIDATION OF A NEW RP HPLC ANALYTICAL METHOD FOR THE DETERMINATION OF ETODOLAC SUCCINIC ACID CO-CRYSTALS IN SPIKED RABBIT PLASMA. Int J Curr Pharm Res. 2023 Mar 15;59–63. doi:10.22159/ijcpr.2023v15i2.2098
38. Bhaskararao P, Sarika M, Madhavi CL, Kollipara MG, Prashanthi G. THE INDUSTRIAL IMPORTANCE OF TECHNOLOGY TRANSFER FOR ANALYTICAL METHOD DEVELOPMENT AND VALIDATION–APPLICATION TO VILAZODONE HYDROCHLORIDE DOSAGE FORM. Int J Chem Res. 2024 Oct 1;12–7. doi:10.22159/ijcr.2024v8i4.235
39. Alenezi SSh, Gouda AA, El Sheikh R, Badahdah NA, Alzuhiri ME, Magrabi AH, Jilani AL, Darwish AS. Environmental sustainability profiles assessment of HPLC stability indicating method for quantitation of piracetam and vincamine in pharmaceutical medications. Talanta Open. 2025 Aug 1;11:100407. doi:10.1016/j.talo.2025.100407
40. Chaudhari M, Parmar PK, Dudhat K. Comparative validation of UV-spectrophotometry and RP-HPLC methods for cefixime and moxifloxacin analysis. Anal Biochem. 2025 Feb 1;697:115724. doi:10.1016/j.ab.2024.115724
41. Patel R, Shah J, Patel M. Analytical Quality by Design Based HPLC for Quantitative Analysis of Teneligliptin and Rosuvastatin Calcium Tablets in the Presence of Force Degradation Products. Sep Sci PLUS. 2025;8(1):e202400229. doi:10.1002/sscp.202400229
42. Karmakar A, Shinde S, Yalamanda V, Khairnar Y, Nayak S, Kumar L. An AQbD-based Optimized and Green Isocratic HPLC Method for the Quantification of Simvastatin in Liposomes: Forced Degradation, Assessment of Drug Content, and Drug Entrapment. J Pharm Innov. 2025 Jun 5;20(3):95. doi:10.1007/s12247-025-09996-1
43. Bangera PD, Keerikkadu M, Tippavajhala VK, Rathnanand M. ANALYTICAL QBD INTEGRATED RP-HPLC METHOD DEVELOPMENT AND OPTIMIZATION FOR HIGH-PRECISION QUANTIFICATION OF IBRUTINIB IN HYBRID NANOCARRIER SYSTEMS. Int J Appl Pharm. 2025 Sep 7;361–77. doi:10.22159/ijap.2025v17i5.54683
44. Ettaboina SK, Nannapaneni S, Katari NK, Chollety VK. Development and Validation of an RP-HPLC Method for Organic Impurity Profiling in Baclofen Utilizing Robustness Through a Quality-by-Design (QbD) Approach: A Comprehensive Forced Degradation Assessment. Biomed Chromatogr. 2025;39(8):e70129. doi:10.1002/bmc.70129
45. Kaddare S, Zakkula A, Bestha RM, Madipelli K, Kumar R, Biradar YB, Veerla N, Dittakavi S, Mullangi R. Validated HPLC-UV Method for the Quantification of a Novel BCr-Abl 1 Inhibitor, Vodobatinib, in Rat Plasma: Application to a Pharmacokinetic Study. Biomed Chromatogr. 2025;39(2):e6077. doi:10.1002/bmc.6077.
Published
How to Cite
Issue
Section
Copyright (c) 2026 MAHESHA KEERIKKADU, PRAGATHI DEVANAND BANGERA, AKSHAY SHETTY, VAMSHI KRISHNA TIPPAVAJHALA, MAHALAXMI RATHNANAND
This work is licensed under a Creative Commons Attribution 4.0 International License.